Tiffany is a Vice President at H.I.G. BioHealth Partners, where she focuses on investment opportunities in the life sciences industry, including biopharmaceuticals, medical devices and diagnostics.
Prior to joining H.I.G., Tiffany was at ZS Associates, where she focused on strategy and transformation initiatives for pharmaceutical and medical device companies in regards to commercial launch strategy, mergers and acquisitions, and change management. Previously, Tiffany began her career at BMO Capital Markets, where she advised healthcare clients on M&A transactions, capital raises and other strategic initiatives.
Tiffany earned her undergraduate degree in Economics and Mathematics, cum laude, from Smith College.
Dylan is a Principal at H.I.G. BioHealth Partners. He is responsible for all aspects of the investment process including originating, structuring, financing and executing post-closing growth and operational strategies. Dylan primarily focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, digital health, pharma services, and healthcare IT.
Prior to joining H.I.G., Dylan worked for CRG and Longitude Capital, where he focused on growth investments across the healthcare sector. He began his career at Bank of America Merrill Lynch, where he advised clients on M&A transactions, capital raises, and other strategic initiatives.
Dylan received his M.B.A. in Health Care Management from the Wharton School at the University of Pennsylvania and his undergraduate degree from Cornell University.
Quentin Langlois is a Vice President at H.I.G. BioHealth Partners where he focuses on investment opportunities in the life sciences industry, including biopharmaceuticals, medical devices, and diagnostics.
Prior to joining H.I.G., Quentin held business development and strategy roles at several biotechnology and pharmaceutical companies, including Theravance Biopharma, aTyr Pharma and Shire (now Takeda), where he primarily assisted in executing licensing and acquisition opportunities across rare diseases, oncology, immunology and other therapeutic areas.
Quentin holds a Bachelor’s degree in Law from UVSQ and a MSc in Management from HEC Paris.
Sami Mnaymneh is a Founder and Co-CEO of H.I.G. Capital. He has directed the firm's development since its founding in 1993 and approves all capital commitments made by H.I.G.
Prior to founding H.I.G., Sami was a Managing Director with The Blackstone Group in New York. Prior to that, he was a Vice President in the Mergers and Acquisitions department at Morgan Stanley & Co., where he devoted a significant amount of his time to leveraged buyouts, serving as senior advisor to a number of prominent private equity firms. Sami has at various times served on a number of academic boards including the Board of Columbia College and the Dean’s Council of the Harvard Law School.
Sami earned a B.A. degree, Summa Cum Laude, from Columbia University where he graduated first in his class, and subsequently received a J.D. degree and an M.B.A. degree, with honors, from Harvard Law School and Harvard Business School, respectively.
As Managing Director of H.I.G. BioHealth Partners, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, RxSight, CardioFocus, Clarus Therapeutics, Iconic Therapeutics, Exagen, and Augmedics.
Bruce has been active in the life sciences sector for more than 30 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on healthcare investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on investments in the US, India, and China. Prior to his private equity career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.
Bruce is on the boards of the University of Delaware Research Foundation and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.
Rick is Co-President of H.I.G. Capital with over twenty-five years of private equity and M&A experience. In his current position, along with Brian Schwartz, he directs the day-to-day operations of the firm and sits on the investment committees for all H.I.G. funds.
Since joining H.I.G. in 1998, he has been involved in all aspects of the investment process; and has held leadership positions in several of the firm’s funds.
Prior to joining H.I.G., Rick worked at General Electric Company and GE Capital. As part of the Corporate Mergers & Acquisitions team, he coordinated a variety of strategic acquisitions in the financial services, plastics, medical systems, electronics, and aerospace industries. Previously, Rick was a member of the GE Corporate Finance Staff, where he helped design and implement improved business strategies and operating processes for GE Capital business units.
Rick received his undergraduate degree with honors from Stanford University and earned his M.B.A. from Harvard Business School.
Brian is Co-President of H.I.G. Capital. He joined the firm in 1994. In his current position, along with Rick Rosen, he directs the day-to-day operations of the firm and sits on the investment committees for all H.I.G. funds.
Since joining H.I.G. in 1994, Brian held a number of leadership positions at the firm.
Prior to joining H.I.G., Brian worked in PepsiCo’s strategic planning group. His responsibilities included managing strategic acquisitions for PepsiCo and evaluating new business opportunities. Brian began his career with the investment banking firm of Dillon, Read and Co. where he split his time between the corporate finance group and the private equity funds, Saratoga Partners and Yorktown Partners.
Brian earned his M.B.A. from Harvard Business School and his B.S. with honors from the University of Pennsylvania.
Tony Tamer is a Founder and Co-CEO of H.I.G. Capital. He has directed H.I.G.'s development since its founding in 1993 and approves all capital commitments made by the firm.
Tony has extensive experience working with, and coaching, early stage and middle-market companies. He currently also serves on the Dean’s Council of the Harvard University Kennedy School of Government.
Prior to H.I.G., Tony was partner at Bain & Company where he developed business unit and operating strategies, and implemented productivity improvement initiatives. Tony also previously held marketing, engineering and manufacturing positions at Hewlett-Packard and Sprint Corporation.
Tony holds an M.B.A. degree from Harvard Business School, and a Masters degree in Electrical Engineering from Stanford University. His undergraduate degree is from Rutgers University.
Gwen is a Managing Director of H.I.G. BioHealth Partners, focusing on investment opportunities in the life sciences sector, including biopharmaceuticals, health care IT, medical devices, and diagnostics.
Gwen has been active in the life sciences sector for more than 28 years. Previously, she served as the General Manager and Vice President of US Robotics for Smith and Nephew and as the Corporate Vice President of Global Corporate Development, Strategy and Strategic Relationships at Teleflex where for eight years she presided over all global acquisitions. Gwen joined Teleflex as a result of Teleflex’s acquisition of Hotspur Technologies, a company Gwen co-founded and served as President and Chief Executive Officer. Gwen was also a co-founder of Nellix Endovascular, Bacchus Vascular and AneuRx, all three of which were medical device companies later acquired by larger strategic players. In addition, Gwen has been general partner of several private equity entities.
Gwen currently serves on the board of Compute Health and is an observer on the board of Augmedics.
Gwen holds an M.S. in Mechanical Engineering from Stanford University, as well as an MBA from Harvard Business School. She also holds a B.S. in Mechanical Engineering from the Massachusetts Institute of Technology where she simultaneously completed her pre-med requirements.
Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Arvelle Therapeutics, Clarus Therapeutics, Leiters Pharmacy, Neurana Pharmaceuticals, Taconic Biosciences, BioVectra, Orbus Therapeutics, and On Target Laboratories.
Prior to H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners.
Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).
Alex is the co-chair of the Industry Advisory Board of the Children’s Tumor Foundation, is on the Advisory Board for Brown University’s Medical School and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America.
He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.